Ann M McNulty
Overview
Explore the profile of Ann M McNulty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Litchfield L, Boehnke K, Brahmachary M, Mur C, Bi C, Stephens J, et al.
Oncotarget
. 2020 May;
11(17):1478-1492.
PMID: 32391118
Aberrant activation of mitogenic signaling pathways in cancer promotes growth and proliferation of cells by activating mTOR and S6 phosphorylation, and D-cyclin kinases and Rb phosphorylation, respectively. Correspondingly, inhibition of...
2.
Blosser W, Dempsey J, McNulty A, Rao X, Ebert P, Lowery C, et al.
Oncotarget
. 2020 Feb;
11(3):216-236.
PMID: 32076484
The combined influence of oncogenic drivers, genomic instability, and/or DNA damage repair deficiencies increases replication stress in cancer. Cells with high replication stress rely on the upregulation of checkpoints like...
3.
Torres-Guzman R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, et al.
Oncotarget
. 2017 Oct;
8(41):69493-69507.
PMID: 29050219
Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in hormone receptor positive (HR+) metastatic breast cancer in...
4.
Konicek B, Stephens J, McNulty A, Robichaud N, Peery R, Dumstorf C, et al.
Cancer Res
. 2011 Jan;
71(5):1849-57.
PMID: 21233335
Activation of the translation initiation factor 4E (eIF4E) promotes malignant transformation and metastasis. Signaling through the AKT-mTOR pathway activates eIF4E by phosphorylating the inhibitory 4E binding proteins (4E-BP). This liberates...
5.
Dumstorf C, Konicek B, McNulty A, Parsons S, Furic L, Sonenberg N, et al.
Mol Cancer Ther
. 2010 Oct;
9(12):3158-63.
PMID: 20971826
Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human...
6.
Graff J, Konicek B, Lynch R, Dumstorf C, Dowless M, McNulty A, et al.
Cancer Res
. 2009 Apr;
69(9):3866-73.
PMID: 19383915
Elevated eukaryotic translation initiation factor 4E (eIF4E) function induces malignancy in experimental models by selectively enhancing translation of key malignancy-related mRNAs (c-myc and BCL-2). eIF4E activation may reflect increased eIF4E...
7.
Graff J, Konicek B, Vincent T, Lynch R, Monteith D, Weir S, et al.
J Clin Invest
. 2007 Sep;
117(9):2638-48.
PMID: 17786246
Expression of eukaryotic translation initiation factor 4E (eIF4E) is commonly elevated in human and experimental cancers, promoting angiogenesis and tumor growth. Elevated eIF4E levels selectively increase translation of growth factors...
8.
Graff J, McNulty A, Hanna K, Konicek B, Lynch R, Bailey S, et al.
Cancer Res
. 2005 Aug;
65(16):7462-9.
PMID: 16103100
Activation of protein kinase Cbeta (PKCbeta) has been repeatedly implicated in tumor-induced angiogenesis. The PKCbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and was advanced for clinical development based upon this antiangiogenic...
9.
Lynch R, Konicek B, McNulty A, Hanna K, Lewis J, Neubauer B, et al.
Mol Cancer Res
. 2005 Mar;
3(3):163-9.
PMID: 15798096
The progression of human prostate cancer from the initial androgen-dependent phase to androgen independence involves diminished apoptosis and a release from the cell cycle block triggered by androgen ablation therapy....
10.
Neubauer B, McNulty A, Chedid M, Chen K, Goode R, Johnson M, et al.
Cancer Res
. 2003 Oct;
63(18):6056-62.
PMID: 14522935
Trioxifene (LY133314) is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor alpha (ERalpha) and antagonistic activity against ERalpha-mediated gene expression. The PAIII rat...